Spirocyclic 1,3-Propane Dioxide Derivatives for GPR40 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for treating hyperglycemia and diabetes lack effectiveness in activating the GPR40 receptor, a key target for managing blood glucose levels.
Innovation Solution
Development of spirocyclically substituted 1,3-propane dioxide derivatives and their physiologically tolerated salts, specifically designed to activate the GPR40 receptor, offering a new therapeutic approach for hyperglycemia treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used for treating hyperglycemia and diabetes, then the treatment approach is established, but the GPR40 receptor activation effectiveness is insufficient
Solution Approach 1:
The patent systematically modifies molecular parameters of the compound structure, including introducing spirocyclic substituents at specific positions (R1, R2, R6), adjusting alkyl chain lengths (C1-C6), incorporating heterocyclic rings (4-12 membered), and varying substituent patterns (fluorine, chlorine, bromine, cyano groups). These parameter changes optimize the compound's binding affinity and activation effectiveness at the GPR40 receptor, transforming insufficient activation into effective therapeutic action.
Solution Approach 2:
The invention creates composite molecular structures by combining spirocyclic core structures with diverse substituent groups. The compounds integrate multiple functional elements: spirocyclic frameworks, alkyl chains, heterocyclic rings, and various substituents (fluorine, chlorine, bromine, cyano, carboxyl, amide groups). This composite approach generates molecules with enhanced pharmacological properties that effectively activate GPR40 receptor while maintaining therapeutic safety profiles.
2Reliability
If new compounds are developed to activate GPR40 receptor, then therapeutic effectiveness is improved, but compound complexity increases
Solution Approach 1:
The patent divides the complex molecular structure into distinct functional segments: a spirocyclic core structure (providing structural framework), substitutable side chains (R1, R2, R6 positions), and functional groups (carboxyl, amide, ester). This segmentation allows systematic variation of individual components to optimize GPR40 activation while managing overall structural complexity through modular design.
Solution Approach 2:
The spirocyclic core structure serves multiple functions simultaneously: it provides the basic molecular framework, enables attachment of diverse substituents, maintains structural rigidity for receptor binding, and offers flexibility in metabolic stability. This multi-functionality reduces the need for separate structural elements, thereby managing complexity while achieving effective GPR40 activation.
3Reliability
If spirocyclically substituted 1,3-propane dioxide derivatives are synthesized, then GPR40 activation is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent employs preliminary synthesis steps where the spirocyclic core structure is first constructed and stabilized, then functional groups and substituents are systematically added in controlled sequences. The 1,3-propane dioxide core is synthesized beforehand as a stable intermediate, allowing subsequent modular attachment of spirocyclic substituents and functional groups. This preliminary action simplifies the overall manufacturing process by breaking down the complex synthesis into manageable stages.
Solution Approach 2:
The patent utilizes intermediate compounds during the synthesis process, such as protected forms of the 1,3-propane dioxide core and stabilized spirocyclic intermediates. These intermediaries facilitate the introduction of complex substituents through well-established chemical transformations, then allow for final deprotection and functional group installation. The intermediaries act as bridges between simple starting materials and the final complex therapeutic compounds, making the manufacturing process more feasible.
Data Source
AI summary
The invention relates to spirocyclically substituted 1,3-propane dioxide derivatives and to their physiologically compatible salts. The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, A and X have the given meanings, and to their physiologically compatible salts. The compounds are suitable for, for example, the treatment of diabetes.